Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

MA Qing-yong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1907-9009; OpenAlex author ID A5102805086. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 3

  1. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. Co-author DOI 10.4251/wjgo.v16.i9.3980↗
  2. Resveratrol Exerts Antitumor Effects on Pancreatic Cancer by Inhibiting Notch Signaling Induced by Chronic Stress Co-author DOI 10.21203/rs.3.rs-2305575/v1↗
  3. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Last author DOI 10.3727/096504014x14024160459122↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guotai Wang · 2 shared papers, 2022–2024 · strength 0.45
  2. He Jiang · 1 shared paper, 2024 · strength 0.28
  3. Zhenhua Ma · 1 shared paper, 2024 · strength 0.28
  4. Zheng Wang · 1 shared paper, 2024 · strength 0.28
  5. Pengli Wang · 1 shared paper, 2022 · strength 0.17
  6. Wanxing Duan · 1 shared paper, 2022 · strength 0.17
  7. Yong Qin · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.